Use of 99mTc-labelled Anti-TNF Monoclonal Antibodies to Assess Patients Affected by Inflammatory Arthropathies

Ceccarelli, Fulvia; Perricone, Carlo; Galli, Filippo; Valesini, Guido; Conti, Fabrizio

doi:10.15344/2456-446x/2015/102

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 99m Tc-adalimumab uptake was not evident in all inflamed joints, most likely because not all inflamed joints are characterized by TNF-α expression, this is important for pre-selection of patients for anti-TNF-α therapy. A mini review compared studies using both 99m Tc-infliximab and 99m Tc-adalimumab and concluded that both antibodies are suitable for therapy decision-making purposes in RA 76. Another interesting observation in that study was that patients that showed high pre-therapy uptake of 99m Tc-adalimumab showed more therapeutic benefit when treated with unlabeled anti-TNF mAb 76,77.…”

Section: Applications Of Molecular Imagingmentioning

confidence: 99%

Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

2020

View full text Add to dashboard Cite

Molecular imaging modalities hold great potential as less invasive techniques for diagnosis and management of various diseases. Molecular imaging combines imaging agents with targeting moieties to specifically image diseased sites in the body. Monoclonal antibodies (mAbs) have become increasingly popular as novel therapeutics against a variety of diseases due to their specificity, affinity and serum stability. Because of the same properties, mAbs are also exploited in molecular imaging to target imaging agents such as radionuclides to the cell of interest in vivo. Many studies investigated the use of mAb-targeted imaging for a variety of purposes, for instance to monitor disease progression and to predict response to a specific therapeutic agent. Herein, we highlighted the application of mAb-targeted imaging in three different types of pathologies: autoimmune diseases, oncology and cardiovascular diseases. We also described the potential of molecular imaging strategies in theranostics and precision medicine. Due to the nearly infinite repertoire of mAbs, molecular imaging can change the future of modern medicine by revolutionizing diagnostics and response prediction in practically any disease.

show abstract

Section: Applications Of Molecular Imagingmentioning

confidence: 99%

Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

2020

View full text Add to dashboard Cite

show abstract

“…To overcome the drawbacks of the excessively long half-life and to reduce non-specific immune recognition, monoclonal antibody fragments and nanobodies (i.e., single-domain antibodies) have been developed. Antibody-based imaging agents have been investigated for their potential application in the diagnosis of autoimmune diseases [99,100], cancer [101,102], and cardiovascular diseases [103].…”

Section: Conjugates For Active Targetingmentioning

confidence: 99%

The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research

et al. 2021

View full text Add to dashboard Cite

Many modern therapeutic approaches are based on precise diagnostic evidence, where imaging procedures play an essential role. To date, in the diagnostic field, a plethora of agents have been investigated to increase the selectivity and sensitivity of diagnosis. However, the most common drawbacks of conventional imaging agents reside in their non-specificity, short imaging time, instability, and toxicity. Moreover, routinely used diagnostic agents have low molecular weights and consequently a rapid clearance and renal excretion, and this represents a limitation if long-lasting imaging analyses are to be conducted. Thus, the development of new agents for in vivo diagnostics requires not only a deep knowledge of the physical principles of the imaging techniques and of the physiopathological aspects of the disease but also of the relative pharmaceutical and biopharmaceutical requirements. In this scenario, skills in pharmaceutical technology have become highly indispensable in order to respond to these needs. This review specifically aims to collect examples of newly developed diagnostic agents connoting the importance of an appropriate formulation study for the realization of effective products. Within the context of pharmaceutical technology research in Italy, several groups have developed and patented promising agents for fluorescence and radioactive imaging, the most relevant of which are described hereafter.

show abstract

“…54 Anti-TNF antibodies such as infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept have been developed to treat inflammatory diseases such as rheumatoid arthritis (RA), spondyloarthropathy, psoriatic arthritis, and IBDs. 55–61…”

Section: Other Monoclonal Antibodiesmentioning

confidence: 99%

Currently Available Radiopharmaceuticals for Imaging Infection and the Holy Grail

Salmanoglu

Kim

Thakur

2018

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Infection is ubiquitous. However, its management is challenging for both the patients and the health-care providers. Scintigraphic imaging of infection dates back nearly half a century. The advances in our understanding of the pathophysiology of disease at cellular and molecular levels have paved the way to the development of a large number of radiopharmaceuticals for scintigraphic imaging of infection. These include radiolabeling of blood elements such as serum proteins, white blood cells (WBCs), and cytokines, to name a few. Infectious foci have also been imaged using a radiolabeled sugar molecule by taking advantage of increased metabolic activity in the infectious lesions. Literature over the years has well documented that none of the radiopharmaceuticals and associated procedures that facilitate imaging infection are flawless and acceptable without a compromise. As a result, only a few compounds such as Tc-hexamethylpropyleneamineoxime,F-FDG, the oldest but still considered as a gold standard In-oxine, and, yes, evenGa-citrate in some countries, have remained in routine clinical practice. Nonetheless, the interest of scientists and physicians to improve the approaches to imaging and to the management of infection is noteworthy. These approaches have paved the way for the development of numerous, innovative radiopharmaceuticals to label autologous WBCs ex vivo or even those that could be injected directly to image infection or inflammation without direct involvement of WBCs. In this review, we briefly describe these agents with their pros and cons and place them together for future reference.

show abstract

Use of 99mTc-labelled Anti-TNF Monoclonal Antibodies to Assess Patients Affected by Inflammatory Arthropathies

Cited by 3 publications

References 5 publications

Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research

Currently Available Radiopharmaceuticals for Imaging Infection and the Holy Grail

Contact Info

Product

Resources

About